Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pediatric phase 3 study of intravenous vedolizumab maintenance therapy in moderate to severe Crohn's disease
MOH_2021-08-11_010194Phase 3Not yet recruiting
- Sponsor
- Takeda
- Start
- May 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of vedolizumab in Crohn's disease (2 arms), sponsored by Takeda. Primary endpoint: Efficacy at week 54 based on clinical and endoscopic assessments. Planned start May 2021; status: not yet recruiting.
02
Drugs
vedolizumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on MOH_2021-08-11_010194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-08-11_010194.